AZD0424

Cat. No.:	HY-112314
CAS No.:	692054-06-1
Molecular Formula:	$C_{25}H_{29}ClN_6O_5$
Molecular Weight:	528.99
Target:	Src; Bcr-Abl; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity[1]. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells[2].
IC_{50} & Target	Src/Abl kinase inhibitor (SrcK-I), apoptosis[1]

In Vitro

AZD0424 (1-5 μM; 24-48 hours) is emerged to be the more effective of the three tested inhibitors (AZM559756, AZD0530 and AZD0424), inducing the highest levels of apoptosis with the lowest concentrations in lymphoma cells[2].
AZD0424 (5 μM; 48 hours) leads to increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells, whereas the cell cycle progression of the nonsensitive cell lines Raji and Jurkat remains unaffected[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[2]

Cell Line:	DOHH-2, WSU-NHL, Raji, Jurkat, Karpas-299 and HUT78 cells
Concentration:	1 μM; 2 μM; 3 μM; 4 μM; 5 μM;
Incubation Time:	24 hours, 48 hours
Result:	Induced apoptosis in lymphoma cells.

Cell Cycle Analysis[2]

Cell Line:	DOHH-2, WSU-NHL, Raji and Jurkat cells
Concentration:	1 μM; 2 μM; 3 μM; 4 μM; 5 μM;
Incubation Time:	48 hours
Result:	Increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells.

REFERENCES

[1]. Woodcock VK, et al. A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. Br J Cancer. 2018 Mar

20;118(6):770-776.

[2]. Nowak D, et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007 Oct;18(9):981-95.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA